@prefix rdf:	<http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix ns1:	<http://linked.opendata.cz/resource/drugbank/drug/> .
@prefix ns2:	<http://linked.opendata.cz/ontology/drugbank/> .
ns1:DB00092	rdf:type	ns2:Drug ;
	ns2:description	"Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD."@en ;
	ns2:generalReferences	"# Koo JY, Bagel J, Sweetser MT, Ticho BS: Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study. J Drugs Dermatol. 2006 Jul-Aug;5(7):623-8. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16865867  # Krell JM: Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept. J Am Acad Dermatol. 2006 Jun;54(6):1099-101. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16713481  # Parrish CA, Sobera JO, Robbins CM, Cantrell WC, Desmond RA, Elewski BE: Alefacept in the treatment of psoriatic nail disease: a proof of concept study. J Drugs Dermatol. 2006 Apr;5(4):339-40. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16673801  # American Society of Health System Pharmacists, Inc., DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995. Alefacept; [updated 2014 Jan 30; cited 2014 Nov 11]. Available from http://web.b.ebscohost.com.login.ezproxy.library.ualberta.ca/dynamed/detail?vid=9&sid=78010ea4-6f9c-4d5a-a7df-a148b3891321%40sessionmgr110&hid=123&bdata=JnNpdGU9ZHluYW1lZC1saXZlJnNjb3BlPXNpdGU%3d#db=dme&AN=232900"@en ;
	ns2:group	"withdrawn"@en ,
		"approved"@en ;
	ns2:halfLife	"~270 hours"@en ;
	ns2:indication	"As an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis"@en .
@prefix owl:	<http://www.w3.org/2002/07/owl#> .
@prefix ns4:	<http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/> .
ns1:DB00092	owl:sameAs	ns4:DB00092 .
@prefix ns5:	<http://bio2rdf.org/drugbank:> .
ns1:DB00092	owl:sameAs	ns5:DB00092 .
@prefix dcterms:	<http://purl.org/dc/terms/> .
ns1:DB00092	dcterms:title	"Alefacept"@en .
@prefix adms:	<http://www.w3.org/ns/adms#> .
@prefix ns8:	<http://linked.opendata.cz/resource/drugbank/drug/DB00092/identifier/pharmgkb/> .
ns1:DB00092	adms:identifier	ns8:PA164748040 .
@prefix ns9:	<http://linked.opendata.cz/resource/drugbank/drug/DB00092/identifier/wikipedia/> .
ns1:DB00092	adms:identifier	ns9:Alefacept .
@prefix ns10:	<http://linked.opendata.cz/resource/drugbank/drug/DB00092/identifier/drugbank/> .
ns1:DB00092	adms:identifier	ns10:DB00092 ;
	ns2:mechanismOfAction	"Inhibits T-lymphocyte activation and production by binding to the CD2 lymphocyte antigen."@en ;
	ns2:packager	<http://linked.opendata.cz/resource/drugbank/company/271B44AC-363D-11E5-9242-09173F13E4C5> ,
		<http://linked.opendata.cz/resource/drugbank/company/271B44AD-363D-11E5-9242-09173F13E4C5> ,
		<http://linked.opendata.cz/resource/drugbank/company/271B44AE-363D-11E5-9242-09173F13E4C5> ;
	ns2:synonym	"ASP0485"@en ;
	ns2:toxicity	"While it has been found to cross the placenta in monkeys, it is not yet known if it also diffuses into breast milk. "@en .
@prefix ns11:	<http://linked.opendata.cz/ontology/sukl/drug/> .
ns1:DB00092	ns11:hasAHFSCode	<http://linked.opendata.cz/resource/AHFS/84-92-00> .
@prefix ns12:	<http://linked.opendata.cz/ontology/mesh/> .
@prefix ns13:	<http://linked.opendata.cz/resource/mesh/concept/> .
ns1:DB00092	ns12:hasConcept	ns13:M0374901 .
@prefix foaf:	<http://xmlns.com/foaf/0.1/> .
ns1:DB00092	foaf:page	<http://www.rxlist.com/cgi/generic3/amevive.htm> ,
		<http://www.drugs.com/cdi/alefacept.html> ;
	ns2:Molecular-Formula	<http://linked.opendata.cz/resource/drugbank/property/271B44B3-363D-11E5-9242-09173F13E4C5> ;
	ns2:Molecular-Weight	<http://linked.opendata.cz/resource/drugbank/property/271B44B2-363D-11E5-9242-09173F13E4C5> .
@prefix ns15:	<http://linked.opendata.cz/resource/atc/> .
ns1:DB00092	ns11:hasATCCode	ns15:L04AA15 ;
	ns2:absorption	"Bioavailability after IM administration is 63%."@en ;
	ns2:affectedOrganism	"Humans and other mammals"@en ;
	ns2:casRegistryNumber	"222535-22-0"@en ;
	ns2:category	"       "@en ;
	ns2:containedIn	<http://linked.opendata.cz/resource/drugbank/medicinal-product/271B44AF-363D-11E5-9242-09173F13E4C5> ;
	ns2:Hydrophobicity	<http://linked.opendata.cz/resource/drugbank/property/271B44B0-363D-11E5-9242-09173F13E4C5> ;
	ns2:Isoelectric-Point	<http://linked.opendata.cz/resource/drugbank/property/271B44B1-363D-11E5-9242-09173F13E4C5> .